Top 5 Drug Type | Count |
---|---|
Small molecule drug | 22 |
Prophylactic vaccine | 8 |
Live attenuated vaccine | 5 |
Combination vaccine | 2 |
Monoclonal antibody | 2 |
Mechanism ACVR2A modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date26 Mar 2024 |
Target |
Mechanism P2X3 receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date20 Jan 2022 |
Target |
Mechanism RdRp inhibitors [+1] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. GB |
First Approval Date14 Nov 2021 |
Start Date15 Nov 2023 |
Sponsor / Collaborator |
Start Date25 Jul 2023 |
Sponsor / Collaborator |
Start Date22 May 2023 |
Sponsor / Collaborator Organon Heist BV [+3] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Measles, Mumps, Rubella and Varicella virus vaccine live(Merck & Co., Inc.) | Chickenpox More | Approved |
Ceftolozane Sulfate/Tazobactam Sodium ( PBP1b x PBP3 x β-lactamase ) | Complicated intra-abdominal infection More | Approved |
Efavirenz ( RT ) | HIV Infections More | Approved |
Sitagliptin Phosphate/Metformin Hydrochloride ( DPP-4 x PRKAB1 ) | Diabetes Mellitus, Type 2 More | Approved |
Raltegravir Potassium ( HIV integrase ) | HIV Infections More | Approved |